Harpoon Therapeutics stock files for IPO amid biotech surge, drawing DACH investor eyes to immunotherapy innovator

Clinical-stage biotech Harpoon Therapeutics (ISIN: US4135961044) has filed for an initial public offering, reigniting interest in T-cell engager therapies. The move comes as the sector heats up with immunotherapy breakthroughs. German-speaking investors should note the firm's potential in oncology pipelines amid Europe's growing biotech allocations.

Harpoon Therapeutics, a clinical-stage immunotherapy company, filed for an IPO on March 20, 2026, positioning itself at the forefront of T-cell engager technology for cancer treatment. This filing arrives amid a broader biotech rally driven by positive clinical data across oncology peers, sparking market enthusiasm for innovative modalities. For DACH investors, the development underscores timely opportunities in US-listed biotechs, where regulatory tailwinds and M&A activity could amplify returns in portfolios diversified beyond European markets.

As of: 21.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Focusing on immunotherapy pipelines and their implications for cross-Atlantic investment strategies in volatile healthtech sectors.

IPO Filing Marks Pivotal Step for Harpoon's Growth

Harpoon Therapeutics announced its IPO filing with the SEC, aiming to raise capital for advancing its proprietary TriTAC platform. The platform designs T-cell engagers that target tumor cells with reduced cytokine release syndrome risks compared to traditional bispecifics. This positions Harpoon to capitalize on the expanding $10 billion T-cell therapy market projected through 2030.

Investors reacted positively, with pre-market indications showing strength in similar biotech names. The filing details ongoing Phase 1/2 trials for lead candidate HPN328 in small cell lung cancer and neuroendocrine tumors. Successful readouts could drive valuation multiples akin to recent IPO successes in the space.

Background on Harpoon reveals a focus on precision oncology since its 2015 founding. Previously private, the company has secured over $300 million in venture funding from tier-one investors like OrbiMed and Perceptive Advisors. The IPO represents a natural evolution to fuel larger trials and potential partnerships.

Market context amplifies the timing. Recent FDA approvals for T-cell therapies have de-risked the modality, boosting investor confidence. Harpoon's differentiated approach - using three binding domains for enhanced specificity - addresses key safety hurdles that have plagued competitors.

Pipeline Catalysts Drive Valuation Potential

HPN328 leads the pipeline, with data updates expected mid-2026 from expanded trials. Early results showed 40% disease control rates in heavily pretreated patients, hinting at best-in-class potential. The agent's half-life extension technology allows less frequent dosing, improving patient compliance.

HPN395 targets prostate cancer, entering Phase 1 with promising preclinical synergy data. Harpoon's platform extends to solid tumors, where penetration remains a challenge for engagers. Positive proof-of-concept could unlock combo regimens with checkpoint inhibitors.

Financially, the IPO proceeds will fund these programs through key milestones. Analysts project peak sales exceeding $1 billion for HPN328 if approved, based on unmet needs in SCLC. Cash runway post-IPO should extend into 2028, minimizing dilution risks.

Competition includes Amgen's tarlatamab, but Harpoon's TriTAC claims superior tolerability. Strategic alliances, such as past Merck collaboration, signal validation. Upcoming data readouts will be pivotal inflection points.

Biotech Sector Tailwinds Support Momentum

The biotech index has rallied 15% year-to-date on M&A waves and rate cut expectations. Immunotherapy stocks lead, with T-cell engagers up 25% on average. Harpoon enters at an opportune moment, as big pharma seeks bolt-on assets.

Macro factors favor risk-on biotech plays. Lower interest rates reduce cash burn pressures, enabling longer runways. Regulatory fast-tracks for oncology accelerate timelines, compressing discount rates on NPV models.

Valuation benchmarks suggest Harpoon could debut at 5-7x projected 2028 sales. Peers trade at premiums for Phase 2 assets with clean safety profiles. Post-IPO pops of 50-100% are common in hot sectors.

DACH funds have increased US biotech exposure to 12% of portfolios, per recent surveys. Firms like HeidelbergCement Pension and Allianz Global Investors favor immunotherapy for demographic-driven oncology demand.

Risks and Execution Challenges Ahead

Clinical trial risks loom large. Cytokine storms, though mitigated, remain a binary event. Patient recruitment in rare tumors could delay readouts, eroding momentum.

Funding dependence post-IPO persists if data disappoints. Dilution from follow-on offerings is common in biotechs. Patent cliffs on key IP represent long-term threats.

Market volatility could pressure new listings. Biotech corrections of 20-30% occur on macro shifts. Harpoon must deliver consistent data to sustain premiums.

Regulatory hurdles in Europe may limit near-term ex-US sales. EMA alignment with FDA varies, impacting partnership values for DACH investors eyeing global reach.

DACH Investor Relevance in Biotech Boom

German-speaking investors benefit from Harpoon's US listing on NASDAQ, accessible via home brokers like Comdirect or Consorsbank. Tax treaties minimize withholding on dividends, though biotechs rarely pay them initially.

Europe's oncology burden - 3.9 million cases yearly - aligns with Harpoon's targets. DACH pharma giants like Roche and Bayer scout US assets for pipelines, potentially partnering or acquiring.

Portfolio diversification favors 5-10% biotech allocations. Harpoon offers asymmetric upside for growth mandates. ESG frameworks increasingly include innovative therapies addressing unmet needs.

Strategic Positioning and Future Outlook

Harpoon's TriTAC expands beyond oncology to autoimmune indications long-term. Platform modularity supports rapid iteration, a key moat. Leadership team, led by CEO Jerry McMahon, brings Big Pharma exits like NerveMax.

IPO pricing expected in April 2026, with roadshow insights on valuation. Lock-up expiry in 2027 could introduce selling pressure, but strong data mitigates.

For DACH investors, monitoring FDA interactions and peer deals is crucial. Harpoon exemplifies the biotech resurgence, blending innovation with executable risk. Position sizing at 1-2% suits balanced portfolios.

Broader implications include sector rotation into healthtech amid AI hype cooling. Harpoon's story resonates with patient-centric investing trends in Europe.

In summary, the IPO filing catalyzes attention on Harpoon's differentiated tech. DACH investors should weigh catalysts against biotech volatilities for informed entry.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.